Characterization of hepatitis B virus X gene quasispecies complexity in mono-infection and hepatitis delta virus superinfection.


Journal

World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448

Informations de publication

Date de publication:
07 Apr 2019
Historique:
received: 24 12 2018
revised: 25 02 2019
accepted: 01 03 2019
entrez: 16 4 2019
pubmed: 16 4 2019
medline: 25 6 2019
Statut: ppublish

Résumé

Hepatitis delta virus (HDV) seems to strongly suppress hepatitis B virus (HBV) replication, although little is known about the mechanism of this interaction. Both these viruses show a dynamic distribution of mutants, resulting in viral quasispecies. Next-generation sequencing is a viable approach for analyzing the composition of these mutant spectra. As the regulatory hepatitis B X protein (HBx) is essential for HBV replication, determination of HBV X gene ( To compare HBV quasispecies complexity in the Twenty-four untreated patients were included: 7/24 (29.2%) with HBeAg-negative chronic HBV infection (CI, previously termed inactive carriers), 8/24 (33.3%) with HBeAg-negative chronic hepatitis B (CHB) and 9/24 (37.5%) with CHD. A serum sample from each patient was first tested for HBV DNA levels. The CHB patients showed higher median HBV-DNA levels [5.4 logIU/mL, interquartile range (IQR) 3.5-7.9] than CHD (3.4 logIU/mL, IQR 3-7.6) ( The lower-replication CHD and CI groups show a trend to higher quasispecies complexity than the higher-replication CHB group. The mechanisms associated with this greater complexity require elucidation.

Sections du résumé

BACKGROUND BACKGROUND
Hepatitis delta virus (HDV) seems to strongly suppress hepatitis B virus (HBV) replication, although little is known about the mechanism of this interaction. Both these viruses show a dynamic distribution of mutants, resulting in viral quasispecies. Next-generation sequencing is a viable approach for analyzing the composition of these mutant spectra. As the regulatory hepatitis B X protein (HBx) is essential for HBV replication, determination of HBV X gene (
AIM OBJECTIVE
To compare HBV quasispecies complexity in the
METHODS METHODS
Twenty-four untreated patients were included: 7/24 (29.2%) with HBeAg-negative chronic HBV infection (CI, previously termed inactive carriers), 8/24 (33.3%) with HBeAg-negative chronic hepatitis B (CHB) and 9/24 (37.5%) with CHD. A serum sample from each patient was first tested for HBV DNA levels. The
RESULTS RESULTS
CHB patients showed higher median HBV-DNA levels [5.4 logIU/mL, interquartile range (IQR) 3.5-7.9] than CHD (3.4 logIU/mL, IQR 3-7.6) (
CONCLUSION CONCLUSIONS
The lower-replication CHD and CI groups show a trend to higher quasispecies complexity than the higher-replication CHB group. The mechanisms associated with this greater complexity require elucidation.

Identifiants

pubmed: 30983817
doi: 10.3748/wjg.v25.i13.1566
pmc: PMC6452231
doi:

Substances chimiques

Trans-Activators 0
Viral Regulatory and Accessory Proteins 0
hepatitis B virus X protein 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1566-1579

Déclaration de conflit d'intérêts

Conflict-of-interest statement: Josep Gregori is an employee of Roche Diagnostics, SL.

Références

Hepatology. 2001 Aug;34(2):404-10
pubmed: 11481626
Prog Drug Res. 2003;60:133-58
pubmed: 12790341
Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8321-6
pubmed: 15919829
Hepatology. 2006 Jun;43(6):1364-74
pubmed: 16729314
J Gen Virol. 2007 Feb;88(Pt 2):432-40
pubmed: 17251560
Genes Cells. 2007 Jul;12(7):863-75
pubmed: 17584298
J Virol. 2008 Feb;82(3):1118-27
pubmed: 18032511
J Gen Virol. 2009 Nov;90(Pt 11):2759-67
pubmed: 19625466
J Hepatol. 2010 May;52(5):658-64
pubmed: 20346531
J Virol. 2011 Jan;85(1):432-9
pubmed: 20962099
J Hepatol. 2011 Nov;55(5):996-1003
pubmed: 21376091
Bioinformatics. 2011 Nov 1;27(21):2957-63
pubmed: 21903629
Semin Liver Dis. 2012 Aug;32(3):228-36
pubmed: 22932971
Antiviral Res. 2013 May;98(2):273-83
pubmed: 23523552
World J Virol. 2012 Jun 12;1(3):71-8
pubmed: 24175212
J Viral Hepat. 2013 Dec;20(12):882-9
pubmed: 24304458
Biochem Biophys Res Commun. 2014 Jan 17;443(3):808-13
pubmed: 24342612
Bioinformatics. 2014 Apr 15;30(8):1104-1111
pubmed: 24389655
J Clin Microbiol. 2014 Sep;52(9):3334-8
pubmed: 24989607
Virus Res. 2015 Jan 2;195:79-85
pubmed: 25172581
Cold Spring Harb Perspect Med. 2014 Nov 03;4(11):a021550
pubmed: 25368018
PLoS One. 2014 Nov 13;9(11):e112306
pubmed: 25393280
Virology. 2015 May;479-480:672-86
pubmed: 25759099
Virology. 2015 May;479-480:46-51
pubmed: 25824477
World J Virol. 2015 May 12;4(2):36-41
pubmed: 25964870
J Clin Transl Hepatol. 2015 Sep 28;3(3):220-9
pubmed: 26623269
PLoS One. 2015 Dec 29;10(12):e0144816
pubmed: 26714168
Virology. 2016 Jun;493:227-37
pubmed: 27060566
PLoS One. 2016 Jun 30;11(6):e0158557
pubmed: 27362848
Nat Rev Gastroenterol Hepatol. 2016 Oct;13(10):580-9
pubmed: 27534692
Antiviral Res. 2016 Dec;136:19-31
pubmed: 27771387
Virus Res. 2017 Jul 15;239:115-125
pubmed: 28040474
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
J Hepatol. 2017 Oct;67(4):669-679
pubmed: 28527664
Virus Res. 2018 Jan 2;243:52-59
pubmed: 28988126
Eur Biophys J. 2018 May;47(4):443-457
pubmed: 29397419
J Hepatol. 2018 Jul;69(1):25-35
pubmed: 29524530
J Med Virol. 2018 Aug;90(8):1328-1336
pubmed: 29663447
World J Gastroenterol. 2018 May 21;24(19):2095-2107
pubmed: 29785078
Viruses. 2018 Jul 09;10(7):
pubmed: 29987240
Antiviral Res. 2018 Oct;158:185-198
pubmed: 30145242
Hepatology. 1987 May-Jun;7(3):569-72
pubmed: 3570167
Nature. 1986 Oct 9-15;323(6088):508-14
pubmed: 3762705
Mol Cell Biol. 1983 Oct;3(10):1766-73
pubmed: 6646122
J Mol Evol. 1980 Dec;16(2):111-20
pubmed: 7463489
Genome Res. 1998 Mar;8(3):186-94
pubmed: 9521922

Auteurs

Cristina Godoy (C)

Liver Pathology Unit, Departments of Biochemistry and Microbiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona 08035, Spain.

David Tabernero (D)

Liver Pathology Unit, Departments of Biochemistry and Microbiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona 08035, Spain.

Sara Sopena (S)

Liver Pathology Unit, Departments of Biochemistry and Microbiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona 08035, Spain.

Josep Gregori (J)

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid 28029, Spain.

Maria Francesca Cortese (MF)

Liver Pathology Unit, Departments of Biochemistry and Microbiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona 08035, Spain.

Carolina González (C)

Liver Pathology Unit, Departments of Biochemistry and Microbiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona 08035, Spain.

Rosario Casillas (R)

Liver Pathology Unit, Departments of Biochemistry and Microbiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona 08035, Spain.

Marçal Yll (M)

Liver Pathology Unit, Departments of Biochemistry and Microbiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona 08035, Spain.

Ariadna Rando (A)

Liver Pathology Unit, Departments of Biochemistry and Microbiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona 08035, Spain.

Rosa López-Martínez (R)

Liver Pathology Unit, Departments of Biochemistry and Microbiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona 08035, Spain.

Josep Quer (J)

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid 28029, Spain.

Gloria González-Aseguinolaza (G)

Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona 31008, Spain.

Rafael Esteban (R)

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid 28029, Spain.

Mar Riveiro-Barciela (M)

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid 28029, Spain.

Maria Buti (M)

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid 28029, Spain.

Francisco Rodríguez-Frías (F)

Liver Pathology Unit, Departments of Biochemistry and Microbiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona 08035, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH